The potential therapeutic implications of reducing RhoA expression levels or using the RhoA/ROCK inhibitor Y27632 in attenuating aberrant type I IFN signaling in SLE should be considered in follow-up studies. Here, RHOA is linked to systemic lupus erythematosus.